Gene expression profiles in skeletal muscle after gene electrotransfer-0

<p><b>Copyright information:</b></p><p>Taken from "Gene expression profiles in skeletal muscle after gene electrotransfer"</p><p>http://www.biomedcentral.com/1471-2199/8/56</p><p>BMC Molecular Biology 2007;8():56-56.</p><p>Published online 29 Jun 2007</p><p>PMCID:PMC1925113.</p><p></p>nsfer, and fixed and stained with hematoxylin and peroxidase-conjugated CD4 antibodies. Representative pictures from 4 slides from the different conditions are depicted

Gene expression profiles in skeletal muscle after gene electrotransfer-1

<p><b>Copyright information:</b></p><p>Taken from "Gene expression profiles in skeletal muscle after gene electrotransfer"</p><p>http://www.biomedcentral.com/1471-2199/8/56</p><p>BMC Molecular Biology 2007;8():56-56.</p><p>Published online 29 Jun 2007</p><p>PMCID:PMC1925113.</p><p></p>here 0 = normal function, 1 = function affected and 2 = function gravely affected. The total score (reflex + motor) is depicted for the following time points pre-treatment, 48 hours, 4 days and 1 week and (n = 12)

FGF-21 mRNA are increased in muscle from subjects with HIV-lipodystrophy and correlates to several measurement of insulin resistance.

<p>(A) Fasting plasma levels of fibroblast growth factor (FGF) 21 are increased 2-fold in HIV subjects with lipodystrophy compared to healthy men; (B) mRNA expression of FGF-21 are increased 8-fold in muscle biopsies from HIV subjects with lipodystrophy compared to healthy men; (C–F) Plots of FGF-21 mRNA in muscle versus several measurements of insulin resistance: FGF-21 mRNA in muscle are positively correlated to fasting insulin (C), HOMA-IR (D), Area under the curve for insulin during an oral glucose tolerance test (E), Area under the curve for C-peptide during an oral glucose tolerance test (F), and negatively correlated to the incremental rate of disappearance of glucose (G), and fractionel velocity of glycogen synthesis (H) in healthy (◊) and HIV subjects with lipodystrophy (•). In the dot plots data for each subjects are given and the line represent means. * P<0.05 and ***P<0.001 for healthy vs HIV-lipodystrophy patients. For plots, linear regression lines, correlations coefficient, and significance levels are given for all subjects.</p

Baseline characteristics of patients and healthy controls.

<p>Data are presented as mean (SD).</p>†<p>Delta, differences between clamp and basal values. HAART, highly active antiretroviral therapy; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non- nucleoside reverse transcriptase inhibitor. HOMA-IR, homeostatic model assessment for insulin resistance, Rate of appearance and disappearance, Rate of appearance and disappearance of glucose during a euglycemic-hyperinsulinemic clamp performed in both HIV patients and healthy controls.</p>*<p><i>P</i><0.05;</p>**<p><i>P</i><0.01;</p>***<p><i>P</i><0.001,</p>****<p><i>P</i><0.0001 by <i>t</i>-test.</p

Additional file 2: of Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial

Appendix A for SPIRIT checklist. Appendix A for SPIRIT checklist. (PDF 170 kb

Additional file 5: Figure S1. of Progressive resistance training in head and neck cancer patients during concomitant chemoradiotherapy -- design of the DAHANCA 31 randomized trial

Illustrations of the exercises. Illustrations of the exercises. (PDF 24 kb

Muscle restoration in cisplatin treated mice.

<p>To evaluate the regenerative response, mice were treated weekly for 6 weeks with cisplatin (4 mg/kg), and then followed for additional 6 weeks. A) Body weight and B) food intake was recorded weekly. C) Lean body mass (LBM) and D) fat mass (FM) was determined by DXA scanning before cisplatin treatment (pre CIS), immediately after the 6 weeks cisplatin treatment (post CIS) and after 6 weeks recovery (post recovery). ND: values below detection limit. Results are presented as means ± SEM. *P<0.05, **P<0.01, ***P<0.001 indicates significant difference compared to baseline control.</p

Treatment completion rates.

<p>Percentage and number of mice completing cisplatin treatment. CON: Saline treated mice, CIS: cisplatin treated mice, ONS: Onsedansetron, STER: steroids, dexamethasone, EX: access to running wheels, and CIS + EX in recovery: access to running wheels in the 6 weeks recovery phase.</p><p>In study 1 in each group, the mice were divided between termination at rest or after 1 hour of acute exercise (swimming). Both groups had the following measurements made: body weight, food intake, weight of organs at termination and blood sampling at termination. In addition, the rest group were DXA scanned, performed the hang tests and had a glucose tolerance test made.</p><p>Treatment completion rates.</p

Effect of anti-emetic medication on body weight and mean food intake.

<p>Mice were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 weeks and received concomitant ondansetron (Zofran) or dexamethasone (DEXA) for 3 consecutive days after each cisplatin treatment. A) Mean food intake, and B) change in body weight. Statistical analysis was performed by oneway ANOVA with Bonferroni's post hoc test (Mean ± SEM, N = 10). *P<0.05, ***P<0.001 compared with Control mice. Linear regression analyses between mean food intake (calculated from 3–5 cages per group) and change in body weight (C+D) (mean of mice in each cage), or change in lean body mass (E+F) (mean of mice in each cage) in non-exercising cisplatin-treated groups (CIS, CIS+Zofran and CIS+DEXA) and exercising cisplatin-treated groups (CIS+DEXA+EX and CIS+EX) were performed.</p

The effect of cisplatin and voluntary wheel running on muscle mass, strength, food intake and body weight.

<p>Mice (n = 16–18) were treated with 4 mg/kg cisplatin (CIS) or saline (Control) once weekly for 6 weeks. During treatment mice were assigned to running wheels in their home cages (Ex) or not. A) Body weight was recorded weekly during the intervention. *** Indicates a significant effect of time (change from baseline, P<0.001), # indicates significant different from the control group (P<0.001)(No Ex = 16, Ex = 18). B) Change in lean body mass (LBM) by DXA scanning before and after the 6 weeks intervention (No Ex = 8, Ex = 9). C) Food intake was recorded per cage with 3 mice. A significant effect of time (P<0.001), cisplatin treatment (P<0.001) and the interaction (P<0.001) between the two was observed (n = 6). D) Weight of TA muscle (No Ex = 16, Ex = 18). E) Weight of heart (No Ex = 16, Ex = 18). F) Fall score from hang test performed 3 days after last cisplatin treatment (No Ex = 8, Ex = 9). Results are presented as means ± SEM. Statistical analysis was performed by 2-way ANOVA with repeated measurements and post hoc test (A, C, D) or post hoc paired T-tests (B) with Bonferroni corrections. * P<0.05, ** P<0.01, ***P<0.001 indicates statistical significance compared to non-exercising control or as indicated by the lines except in A) or ^$P<0.05 compared to pre-treatment levels (B).</p